Learning Objectives After completing this course, the reader should be able to: Describe the epidemiology of leptomeningeal metastasis. Participate in the diagnosis of leptomeningeal metastasis. Engage in the treatment of leptomeningeal metastasis. This article is available for continuing medical education credit at CME.TheOncologist.com Background. Neoplastic meningitis (NM) is a common problem in neuro‐oncology, occurring in approximately 5% of all patients with cancer. Methods. Notwithstanding frequent focal signs and symptoms, NM is a disease affecting the entire neuraxis, and therefore staging and treatment need encompass all cerebrospinal fluid (CSF) compartments. Results. Central nervous system staging of NM includes contrast‐enhanced cranial computerized tomography or magnetic resonance imaging (MR‐Gd), contrast‐enhanced spine magnetic resonance imaging or computerized tomographic myelography and radionuclide CSF flow study. Treatment of NM incorporates involved‐field radiotherapy of bulky or symptomatic disease sites and intra‐CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with NM and may obviate the need for intra‐CSF chemotherapy. At present, intra‐CSF drug therapy is confined to three chemotherapeutic agents (i.e., methotrexate, cytosine, arabinoside, and thio‐TEPA) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Conclusions. Although treatment of NM is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM. This review summarizes the epidemiology, diagnosis, and treatment of neoplastic meningitis.